Abstract. Insulin-like growth factor 1 receptor (IGF-1R) inhibitors have been developed as potential therapeutics for cancer treatment; however, the phase III trials have not produced promising overall survival rates. Therefore, understanding the mechanism underlying intrinsic resistance to IGF-1R-targeted agents is urgently required. A number of studies have revealed that activation of alternative receptor tyrosine kinases can mediate resistance to IGF-1R-targeted therapy. The present study investigated whether activated mesenchymal-epithelial transition factor (MET; also known as c-Met and hepatocyte growth factor receptor) confers resistance to an IGF-1R inhibitor (NVP-AEW541) of gastric cancer (GC) cells. NCI-N87 and MGC-803 cells were treated with varying concentrations and combinations of NVP-AEW541, hepatocyte growth factor (HGF) and MET small interfering (si)-RNA or crizotinib (a MET inhibitor). The effects of these agents on cell proliferation and pro-apoptotic events were assessed by Cell Counting Kit-8 assays and flow cytometry. Receptor activation and the downstream signaling pathway were examined using western blot analysis. Expression and/or activation of MET and IGF-1R in 156 GC specimens were evaluated by immunohistochemistry. The results demonstrated that NVP-AEW541 inhibited cell growth, with dephosphorylation of IGF-1R and protein kinase B (AKT), in NCI-N87 and MGC-803 cells. Application of HGF activated MET and the downstream AKT signaling pathways, decreased apoptotic events and restored cell proliferation, which were reversed by MET inhibition via crizotinib or siRNA knockdown. Furthermore, combination therapy of NVP-AEW541 and crizotinib exhibited an enhanced effectiveness in vitro. In addition, >40% of IGF-1R overexpressed GC specimens showed MET expression and activation. In conclusion, HGF-induced MET activation may represent a novel mechanism conferring unresponsiveness to IGF-1R-targeted agents in GC, and inhibition of MET may improve the efficacy of IGF-1R inhibitors.
Introduction
Gastric cancer (GC) is the fourth most common type of malignant tumor and is the second leading cause of cancer-associated mortality (1) . Recent therapeutic strategies have focused on molecularly targeted therapies, evaluating the numerous successes of molecular targeted therapy in different types of cancer, as well as the absence of overlapping toxicity with current cytotoxic drugs.
Insulin-like growth factor 1 receptor (IGF-1R) has been proposed as a potentially effective target for cancer treatment, as it serves an important role in tumor cell survival and tumorigenesis via the mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signaling pathways; its overexpression has been reported in many types of cancer (2) (3) (4) . Early phase clinical trials of the IGF-1R monoclonal antibody (mAb) figitumumab revealed anticancer activities in non-small-cell lung cancer with an improved objective response rate (from 42 to 54%) (5, 6) . Unfortunately, phase III trials of figitumumab were recently discontinued as the interim analysis indicated that the IGF-1R mAb was unlikely to improve overall survival. Thus, understanding of the underlying mechanisms of intrinsic resistance to IGF-1R-targeted therapies is urgently required.
Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells
Mesenchymal-epithelial transition factor (MET), also known as c-Met, the receptor tyrosine kinase (RTK) for hepatocyte growth factor (HGF), is frequently amplified and/or overexpressed in GC (7, 8) . MET activation through amplification or HGF leads to a cascade of events, including MAPK and AKT signaling, common downstream targets of the IGF-1R. An increasing body of evidence has supported that 'cross-talk' between RTKs may result in the activation of one such receptor via signaling pathways mediated by a different RTK. In addition, activation of bypass RTKs is now considered to be a widespread innate or acquired resistance mechanism in targeted therapies (9) (10) (11) (12) . Previous studies have revealed that activation of epidermal growth factor receptor and insulin receptor (IR) may represent potential resistance mechanisms to IGF-IR-targeted therapy via alternative signaling pathways (13, 14) . Cross-talk between IGF-1R and MET has been reported previously, as in cancer cells co-expressing IGF-1R and MET, IGF-1R activation lead to a delayed phosphorylation of MET, independent of HGF (15); MET is also required for IGF-I-mediated migration and invasion (16, 17) .
Therefore, the aim of the present study was to determine whether MET activation had an impact on resistance to the IGF-1R tyrosine kinase inhibitor (TKI), NVP-AEW541, in GC cell lines. It was observed that HGF-induced MET activation led to resistance to IGF-1R TKI by restoring AKT pathway signaling, which was reversed by crizotinib application, a MET TKI (18) , or MET silencing. Furthermore, MET activation was observed more frequently in GC patients with IGF-1R overexpression. Understanding the cross-talk between IGF-1R and MET could be helpful for patient selection and treatment strategies for IGF-1R inhibitors.
Materials and methods
Cell lines. NCI-N87 and HGC-27 human GC cells were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). MKN-45, MKN-28 and MGC-803 GC cells were obtained from 3D Biopharm Biotech Co., Ltd. SNU-216 cells were sourced from Medical College of Xiamen University (Fuzhou, China). Cell lines were tested and authenticated by short tandem repeat DNA profiling analysis. Particularly, MKN28 cell line has been reported to be contaminated, the contaminating cell line is MKN74, of the gastric tubular adenocarcinoma type (19) . Cells were cultured in minimum essential medium (for HGC-27 cells) or in RPMI-1640 medium containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C in a humidified atmosphere with 5% carbon dioxide.
Chemicals. NVP-AEW541 was provided by Novartis International AG (Basel, Switzerland) and crizotinib was purchased from Selleck Chemicals (Houston, TX, USA). Recombinant human HGF was purchased from PeproTech, Inc., (Rocky Hill, NJ, USA). Compounds were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and diluted with culture medium to the desired concentration with a final DMSO concentration of <0.2% (v/v). DMSO was added to culture medium as a solvent control. RNA interference transfection. For small interfering (si)-RNA experiments, N87 or MGC-803 cells were firstly seeded, then following 24 h, MET siRNA or scrambled siRNA (sense 5'-CAA CAC CCA TCC AGA ATG TCA-3' and antisense 5'-TGA CAT TCT GGA TGG GTG TTG-3'; final concentration, 10 nmol/l) was incubated with HiperFect Transfection Reagent to allow for the formation of transfection complexes, which were then added to cells for transfection. Scrambled siRNA (Qiagen, Inc., Valencia, CA, USA) was used as the negative control. Following 24 h post-transfection, the medium was removed and cells were treated as indicated. Cell viability was determined using a CCK-8 Cell Viability Assay or Clonogenic Assay (performed as aforementioned).
Western blot analysis. Cells were lysed in radioimmunoprecipitation assay buffer supplemented with a complete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Protein content in the cell lysates was quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China) to ensure that all samples contained similar amounts of protein. Antibodies against MET (25H2), phosphorylated (p)-MET (Tyr1234/1235), IGF-1R β, p-IGF-1R β (Tyr1135/1136), AKT, p-Akt (Ser473), p42/44 MAP, and p-p42/44 MAPK (Thr202/Tyr204) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies against β-actin were from Jackson Laboratory (Bar Harbor, ME, USA). Blots were probed with the indicated primary antibodies, then with horseradish peroxidase (HRP)-conjugated secondary antibody. Proteins were detected using the enhanced chemiluminescence reagent, Pierce Enhanced Chemiluminescence Western Blotting Substrate (Thermo Fisher Scientific, Inc.).
Detection of apoptosis.
Cell apoptosis was detected using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Briefly, NCI-N87 and MGC-803 cells (6x10 5 per well) were cultured in 6-well plates and treated with either NVP-AEW541 or HGF alone or in combination with crizotinib for 12 h. The floating and trypsinized adherent cells were then harvested and stained with Annexin V and propidium iodide. Quantitative analysis was performed with a Cytomics FC 500 flow cytometer (Beckman Coulter, Inc., Brea, CA, USA) using CXP software (Beckman Coulter, Inc.). Cells positive for early apoptosis exhibited Annexin V-FITC staining only. Assays were performed in triplicate.
Patients and specimens. A total of 156 primary gastric adenocarcinoma specimens were obtained by surgical resection between 2007 and 2010 at Shanghai Cancer Hospital, Fudan University (Shanghai, China). Samples were acquired with patient written informed consent, using the protocol approved by the Shanghai Cancer Hospital Research Ethics Committee. Paraffin blocks were selected according to the availability of suitable formalin-fixed, paraffin-embedded tissue and complete clinicopathologic and follow-up data (n=154 samples). Tumor staging was determined according to the Tumor-Node-Metastasis classification system of the American Joint Committee on Cancer, 7th edition.
Tissue microarray and immunohistochemistry (IHC).
Tissue microarrays were constructed in collaboration with Shanghai Biochip (Shanghai, China), as described previously (20) . All samples from GC patients were reviewed histologically following hematoxylin and eosin staining. Representative cores were taken from paraffin blocks, in selected areas away from necrotic and hemorrhagic regions.
The commercially available primary antibodies used for IHC assays were as follows: Antibodies against IGF-1R and p-IGF-1R (Y1161) were from Abcam (Cambridge, UK). An anti-Total c-MET (SP44) rabbit monoclonal primary antibody was from Roche Diagnostics. Antibodies against p-MET (Tyr1234/1235) were from Cell Signaling Technology, Inc. IHC of paraffin sections was performed using a 2-step protocol (MaxVision HRP-Polymer Detection System; Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) according to the manufacturer's instructions. Briefly, paraffin sections were deparaffinized and then rehydrated. Following microwave antigen retrieval, endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide. Non-specific binding sites were blocked with phosphate buffered saline containing 10% normal goat serum. Following staining with primary antibodies and peroxidase polymer-conjugated secondary antibody, sections were incubated with diaminobenzidine solution and counterstained with hematoxylin. Negative control slides without the primary antibodies were included for all samples.
Immunostaining scoring system. Slides were independently evaluated by two investigators who were blinded to the clinical information. For MET and IGF-1R staining, only tumor cell membrane staining was considered (2, 21, 22) . Immunostaining was scored according to a semiquantitative 4-grade scale, as follows: 0, no positive staining or <10% positively stained cells in tumor; 1+, 10-40% positively stained cells in tumor; 2+, 40-70% positively stained cells in tumor; and 3+, >70% positively stained cells in tumor. Samples assigned scores of 2+ or 3+ were considered to have overexpression of the respective protein, and those with scores of 0 or 1+ were considered to have no expression or moderate expression. p-MET and p-IGF-1R were scored as follows: 0, absent; 1+, weak; 2+, moderate; and 3+, strong, with consideration of the proportion and intensity of the staining pattern in tumor cytoplasm, membrane or nucleus (21) .
Statistical analysis. Statistical analyses were performed with GraphPad Prism v.7.0 (GraphPad Software, Inc., La Jolla, CA, USA). The data of functional experiments were expressed as the mean ± standard deviation from three independent experiments. IC50 of the GC cells were calculated using a nonlinear regression model. Differences between cell viability and growth curves were analyzed by two-way ANOVA followed by the Bonferroni multiple comparison test. Quantitative variables were analyzed by the Student's t-test or one-way ANOVA with Bonferroni posttest. All tests were two-sided. P<0.05 was considered to indicate a statistically significant difference.
Results

MET expression impacts NVP-AEW541 sensitivity.
The GC cell lines selected for the present study, MKN-28, SNU-216, NCI-N87, MGC-803, HGC-27 and MKN-45, displayed varying sensitivities to IGF-1R inhibition by NVP-AEW541 (Fig. 1A) . As shown in Fig. 1B , expression of IGF-1R was not necessarily the only factor able to determine sensitivity to NVP-AEW541. Notably, MKN-45, which had significantly enhanced expression and activation of MET, exhibited the greatest levels of unresponsiveness to NVP-AEW541. Accordingly, it was hypothesized that MET expression may have an impact on NVP-AEW541 sensitivity. Particularly, although MKN28 cell line is of mixed GC type, this has no impact on interpretation of this figure. Accordingly, it was hypothesized that MET expression may have an impact on NVP-AEW541 sensitivity.
NVP-AEW541 sensitivity is abrogated by HGF treatment in NCI-N87 and MGC-803 cells.
When NCI-N87 and MGC-803 cells were exposed to NVP-AEW541, NVP-AEW541 exerted a cancer cell inhibitory effect in a dose-dependent manner. To verify the role of MET activation in conferring NVP-AEW541 resistance, NCI-N87 and MGC-803 cells were treated with HGF, the corresponding MET ligand, and then exposed to NVP-AEW541. HGF significantly increased the number of NVP-AEW541-resistant colonies in NCI-N87 and MGC-803 GC cells (P<0.001), thereby attenuating the inhibitory effect of NVP-AEW541 (Fig. 2) .
NVP-AEW541 sensitivity is restored by MET blocking or silencing in the presence of HGF.
The MET TKI crizotinib alone caused moderate cell growth inhibition only. When NCI-N87 and MGC-803 cells were treated with a combination of NVP-AEW541, HGF and crizotinib, HGF-mediated resistance to NVP-AEW541 was abrogated completely and growth inhibitory effects were restored ( Fig. 2A and B) , which could be explained by MET blocking as opposed to the side effects of crizotinib.
As crizotinib is a multi-target inhibitor of RTKs, including anaplastic lymphoma kinase, MET, Recepteur d'Origine Nantais and ROS proto-oncogene 1 RTK (18), in order to validate that IGF-1R inhibitor resistance could be attenuated by MET inhibition, the present study knocked down the MET gene using specific siRNAs. Knockdown of MET was confirmed by western blot analysis in NCI-N87 and MGC-803 cells (Fig. 2E) . When the two silenced groups in NCI-N87 and MGC-803 cells were treated with NVP-AEW541 and HGF, HGF-induced resistance to NVP-AEW541 was inhibited ( Fig. 2C and D) . Thus, it was indicated that HGF induced NVP-AEW541 resistance via MET activation.
HGF decreases the number of apoptotic events in NVP-AEW541-treated NCI-N87 and MGC-803 cells. NCI-N87
and MGC-803 cells underwent apoptosis when incubated for 18 h with NVP-AEW541. The results revealed that HGF reduced the percentage of pro-apoptotic cells in the NCI-N87 and MGC-803 cell lines from 14.3 to 9.3% (P<0.05) and 5.7 to 3.9%, respectively. Treating NCI-N87 and MGC-803 cells with a combination of HGF and crizotinib restored the pro-apoptotic effects of NVP-AEW541 by increasing the percentage of pro-apoptotic cells to 12.6 and 20.1%, respectively (P<0.05; Fig. 3 ).
HGF decreases NVP-AEW541 sensitivity via MET-dependent upregulation of AKT signaling.
To explore the mechanism by which HGF decreased NVP-AEW541 sensitivity and the number of apoptotic events, the present study examined the activation status of downstream signaling molecules. MGC-803 and NCI-N87 cells were exposed to NVP-AEW541, HGF and crizotinib as indicated, and the activation status of membranous receptors and downstream signaling pathways were detected by western blotting (Fig. 4) . Treatment with NVP-AEW541 resulted in the dephosphorylation of IGF-1R and AKT, as opposed to extracellular signal-regulated kinase, in NCI-N87 and MGC-803 cells. The presence of HGF led to MET phosphorylation and reactivation of AKT. When cells were treated with a combination of NVP-AEW541 and crizotinib, the inhibition of IGF-1R and MET led to the sustained inhibition of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, even in the presence of HGF, which suggested that dual receptor inhibition may lead to an optimal clinical efficacy.
Combined administration of NVP-AEW541 and crizotinib exerts an enhanced effectiveness.
To evaluate the potential of combination therapy, the present study treated NCI-N87 and MGC-803 cells with NVP-AEW541 and crizotinib, and then analyzed the effects of dual receptor inhibition on cell viability. Treatment of NCI-N87 cells with either NVP-AEW541 or crizotinib resulted in a relatively modest inhibition response, whereas treatment with the drugs combined led to a significantly enhanced growth inhibition response (Fig. 5) . In addition, MGC-803 cells exhibited a similar response to dual receptor inhibition, suggesting that combination therapy targeting IGF-1R and MET may be effective in the clinic.
MET expression and activation in GC samples overexpressing IGF-1R.
To establish the potential of MET activation in IGF-1R inhibitor candidate biomarkers, the present study detected the expression and/or activation profile of MET and IGF-1R in 156 primary gastric surgical samples by IHC, and summarized the clinicopathologic characteristics of the patients (data not shown). A total of 154 primary GC samples were suitable for IHC assessment. MET, p-MET, IGF-1R and p-IGF-1R expression was detected in 68 (44.2%), 51 (33.1%), 120 (77.9%) and 86 tumors (55.8%), respectively. In addition, there were significantly more MET expressed and activated cases in patients with IGF-1R overexpressing tumors than in those with IGF-1R negative/moderately expressed tumors (MET, 69.8 vs. 26.4%, P<0.0001; p-MET, 42.9 vs. 26.4%, P<0.05; Table I ). Two representative samples of patients with positive expression or activation of MET and IGF-1R are presented in Fig. 6 .
Discussion
The role of IGF-1R in tumorigenesis and oncogenic transformation is well established as a cancer treatment target of particular interest. However, several phase III clinical trials have revealed that the IGF-1R inhibitor is less likely to be effective, even in cases expressing IGF-1R; thus, further investigation in the mechanisms underlying resistance are required. In the present study, the results demonstrated that MET activation is a novel mechanism of IGF-1R inhibitor resistance in GC cells by activating downstream AKT signaling and blocking MET via TKI or siRNA, thus, re-sensitizing GC cells to IGF-1R inhibition in vitro.
Inhibition of RTKs often results in the alternative activation of other RTKs, thus restoring the downstream PI3K and MAPK signaling pathways. Previous studies have revealed that insulin receptor activation represents a resistance mechanism that limits the efficacy of IGF-1R targeting (14, 23) ; however, this cannot fully explain the results that the dual IGF-1R/IR inhibitor OSI-906 showed a lack of efficacy in investigational colorectal cancer patients.
The present study revealed that MET-activated MKN-45 cells, which have a similar IGF-1R expression profile to those of the IGF-1R inhibitor-sensitive HGC-27 and NCI-N87 cells, were resistant to the IGF-1R inhibitor, NVP-AEW541. This result suggested that MET expression may have impact on NVP-AEW541 sensitivity.
HGF-induced MET activation can rescue NCI-N87 and MGC-803 cells from NVP-AEW541 mediated growth inhibition. MET phosphorylation reactivated the common downstream PI3K/AKT signaling pathway, subsequently decreasing the frequency of pro-apoptotic events in NCI-N87 and MGC-803 cells. Furthermore, administration of MET-TKI or MET knockdown reversed this effect and restored NVP-AEW541 sensitivity in HGF-treated cancer cells. In addition, crizotinib induced a prominent reduction in the level of AKT activation together with the IGF-1R inhibitor in the presence of HGF, resulting in a greater number of apoptotic events.
As the results revealed, treatment with NVP-AEW541 inhibited the cell growth of NCI-N87 and MGC-803 cells by blocking PI3K/AKT signaling as opposed to MAPK signaling; this result is in agreement with a previous study in which NVP-AEW541 had no or only a weak effect on inhibiting MAPK activation in esophageal, colon and biliary tract cancer (24) (25) (26) (27) . Knockdown of IGF-1R inhibited the phosphorylation of AKT; however, it had no effect on ERK (28) . This suggested that the bioactivity of the IGF-1/IGF-1R axis may be more dependent on the PI3K/AKT signaling pathway compared with the MAPK signaling pathway; however, on the other hand, sustained MAPK activity may have a potential influence on limiting the efficacy of the IGF-1R inhibitor.
Additionally, as shown in the clonogenic assay, crizotinib had little effect as a single agent on NCI-N87 and MGC-803 cell proliferation, indicating that crizotinib alone did not exhibit marked antitumor activity. It was also noted that there was dephosphorylation of IGF-1R in NCI-N87 and MGC-803 cells treated with crizotinib. This result is consistent with several studies supporting cross activation between IGF-1R and MET receptors (16, 29) . It is likely that blocking one of the two receptors will lead to reshuffling of the downstream signaling pathways and in turn, affect the other receptor (30) .
Notably, co-expression of MET and IGF-1R is a common phenomenon and has been detected in a broad range of types of cancer (18, 31, 32) . Although MET gene amplification accounts for a small subset of GCs (7, 33, 34) , high levels of MET protein and MET activation are commonly encountered (7) . In the present study, MET expression and activation were observed in 44.2 and 33.1% gastric tumor samples, respectively. Furthermore, a large proportion of IGF-1R overexpressing gastric tumors (42.9%) have MET activation, which may lead to IGF-1R/IR inhibitor resistance. This result established the feasibility of patient enrichment with a MET profile, and the potential clinical application of combined therapy.
In conclusion, to the best of our knowledge, this is the first study to show that HGF-induced MET activation represents a novel resistance mechanism of IGF-1R inhibition in GC cells. Therefore, the detection of MET receptor status should be taken into consideration when recruiting patients into IGF-1R inhibitor clinical trials, and simultaneous MET inhibition may be required to overcome primary and/or acquired IGF-1R inhibitor resistance. Table I . Association between MET and IGF-1R expression status. MET, mesenchymal-epithelial transition factor; p, phosphorylated; IHC, immunohistochemistry; IGF-1R, insulin-like growth factor 1 receptor.
IGF-1R IHC status -----------------------------------------------------------------------
